Roche is suspending planned investments in Germany – but is leaving the door open
The Basel-based pharmaceutical manufacturer Roche is outraged about the price discounts that the German government is forcing him to make. In the event that Berlin moves closer to the pharmaceutical industry again, he signals willingness to compromise.
Roche, a Basel-based pharmaceutical company, has expressed outrage over price cuts forced by the German government. The company has put all future investment decisions in Germany on hold, citing a new law that requires drug manufacturers to offer additional discounts. Roche has invested €3.8 billion in German sites since 2020, creating over 1,800 new jobs, and currently employs around 18,600 people in the country. The company is open to compromise if Berlin revisits its approach to the pharmaceutical industry.
Written by urgent.news from NZZ Wirtschaft's report — not a translation of it. Machine-written — may contain errors; check the original before relying on it.
This story
This is one outlet's version. Read the fullest account.
- Investments: Government courts investors: "Germany is back" handelsblatt.com
